Merck's ( NYSE: MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, ...

(SMMT) stock rises as its lung cancer drug ivonescimab with chemotherapy hit the main goal in a Phase 3 trial for lung cancer ...

US FDA grants priority review status to Bayer’s sevabertinib to treat patients with HER2-mutant non-small cell lung cancer: Berlin Friday, May 30, 2025, 16:00 Hrs [IST] Bayer an ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Cediranib is an orally available pan-VEGFR tyrosine kinase inhibitor with a half-life of 22 hours compatible with once daily dosing. 15 Cediranib has a subnanomolar 50% inhibitory concentration for ...

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

The therapy claims to be the first therapeutic agent to utilise molecularly defined biomarkers for precision-targeted HCC ...

SU11657 (SUGEN) is a selective multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity exerted by targeting PDGF receptors ... All antibodies were diluted in 0.1% ...

Names like idarucizumab, levetiracetam and ustekinumab may look like words from Greek or Norse mythology, but they're chosen ...

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...

Daiichi Sankyo & Merck voluntarily withdraws patritumab deruxtecan BLA to treat locally advanced or metastatic EGFR-mutated NSCLC from US FDA: Basking Ridge, New Jersey Friday, Ma ...